{
  "report_rows": [
    {
      "kpi": "Total Company Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$815M vs. cons $803M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.50 vs. cons $1.42",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Gross Margin (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~68.5% vs. cons ~69.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Total Revenue Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~22% (21-23% range) vs. cons ~22% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted EPS Growth Guidance",
      "prediction": "LOWER",
      "answer": "guide ~24% vs. cons ~28% (>25% prior guide) (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted Operating Margin Expansion",
      "prediction": "LOWER",
      "answer": "guide ~+50bp vs. cons ~+100bp (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -4.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -6.5,
  "day5_path": "FADE",
  "day5_rationale": "Even if Q2 headline revenue/EPS beat, gross margin miss from ongoing warranty/E&O costs tied to both 2026 device corrections plus an implicit trim to the FY EPS-growth (>25%) and operating-margin-expansion targets will force sell-side models to cut H2 estimates, echoing the May pattern where a beat-and-raise quarter still sold off; litigation overhang (lead plaintiff deadline Aug 31) and looming Tandem tubeless competition keep sentiment fragile, so any initial relief bounce likely fades as analysts revise 2H26/2027 numbers down.",
  "day5_confidence": "MEDIUM"
}